News | November 10, 2021
Marksons Pharma PAT slips to Rs 46.28 in Q2FY22
Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021
Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021
The company has tied up with OrbiMed as a financial partner for global reach
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
But acquisition charges drag earnings into loss
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
Relonchem receives marketing authorization for Moxonidine tablets
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The Subsidiary has received one inspectional observation in Form 483
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
